Tradestie Institutional Equity Comparison Engine

YDES vs VRXA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

YDES Overall Edge

YDES Captures Institutional Edge (2โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to YD Bio Limited Ordinary Shares (YDES) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, YDES trades at N/M Forward P/E with -528.7% operating margin (+314.9% YoY revenue) versus VRXA at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, YDES sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against VRXA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
YDES N/M vs VRXA N/M Fwd P/E
Growth & Margin Winner YDES
Op Margin -528.7% vs N/A ยท YoY +314.9% vs N/A
Momentum & Technical Winner YDES
1Y -48.1% vs -95.8% ยท 52W Pos 22% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
YDES NASDAQ
YD Bio Limited Ordinary Shares
Services-Medical Laboratories
$4.83
+5.92% 1D
Market Cap $323.0M
1M Return +13.92%
1Y Return -48.06%
Forward P/E N/M
Unified AI Score
49.0 / 100 HOLD
Tech 31.0 Fund 35.0 Flow 50.0 Mom 40.0
VRXA US Equity
VRXA
Institutional Equity
$1.04
+0.97% 1D
Market Cap N/A
1M Return +0.97%
1Y Return -95.8%
Forward P/E N/M
Unified AI Score
41.6 / 100 SELL
Tech 30.0 Fund 41.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: YDES -48.06% VRXA -95.8% Spread: +144.42 pp (YDES Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
YDES TTM Op. Margin: -528.7% VRXA TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on YDES vs VRXA. Trailing 12-month operating profitability (YDES -528.7% vs VRXA N/A) and valuation multiples (YDES N/M vs VRXA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: YDES (7) vs VRXA (1)
Institutional Metric YDES VRXA Criterion Row Winner
Market Capitalization Scale $323.0M N/A Larger Scale YDES
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +314.9% N/A Higher Growth YDES
Operating Margin (TTM) Profitability -528.7% N/A Higher Margin YDES
Net Profit Margin Profitability 24.7% N/A Higher Margin YDES
Return on Equity (ROE) Capital Efficiency -42.7% N/A Higher ROE YDES
52-Week Range Position Momentum 22% ($2โ€“$16) 0% ($1โ€“$27) Stronger Trend YDES
Beta / 30D Volatility Risk Regime -0.07ฮฒ ยท 139% Vol 1.16ฮฒ ยท 104% Vol Lower Realized Risk VRXA
Unified Institutional Score Composite Signal 49.0 / 100 (HOLD) 41.6 / 100 (SELL) Higher Composite YDES

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full YDES vs VRXA Buy Guide
YDES UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live YDES Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VRXA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VRXA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither YDES nor VRXA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.